Conference Track

Highlight on Special Hepatic Issues and Populations

Source: CCO Independent Conference Coverage of the 2007 Annual Meeting of the American Association for the Study of Liver Diseases*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Capsule Summaries

Favorable HCV, HBV Outcomes in HCV/HBV-Coinfected Patients Treated With Peginterferon alfa-2a Plus Ribavirin
Robust Response to Peginterferon alfa-2b Plus Ribavirin Among HCV-Infected IV Drug Users on Opioid Maintenance in Large German Cohort
Significant Proportion of HCV/HIV-Coinfected Patients Refuse HCV Therapy in Large German Cohort
Development of Model for End-Stage Liver Disease Improved Graft and Overall Survival Rates After Liver Transplantation in HCC Patients
Substitution of HBIg With ADV in HBV Patients Following Liver Transplantation Receiving LAM and HBIg Prophylaxis
FibroScan Better Than Serum Markers for Predicting Presence of Cirrhosis in Hepatitis C Patients
Steroid-Free Immunosuppression Following Liver Transplantation Effective in Reducing Rate of HCV Recurrence and Severe Fibrosis
Interim Analysis Suggests Prophylactic Peginterferon alfa-2a Plus Ribavirin Tolerable and Effective in Preventing HCV Recurrence After Liver Transplantation
Sex, Age, ALT, and HCV Infection All Identified as Important Risk Factors for Developing HCC
Uptake of HCV Treatment Extremely Low Among Inner-City Residents in Vancouver Despite Very High Prevalence and Incidence of HCV Infection in This Population
Hepatic Steatosis in HBV-Infected Individuals Related to Host Factors, Not Viral Factors
Preemptive Lamivudine Protective Against HBV-Related Morbidity and Mortality in HBsAg-Positive Cancer Patients Receiving Chemotherapy
Pioglitazone Improves Liver Histology in Nondiabetic Patients With NASH
Insulin Resistance Shown to Be Predictive of Fibrosis Progression in Genotype 1 HCV Patients

Expert Analysis

Special Hepatic Issues and Populations

Faculty:

Robert J. Fontana, MD
Stephen A. Harrison, MD, FACP
David L. Thomas, MD, MPH

Learning Objectives

Upon completion of this activity, participants should be able to:

Describe data regarding the management of patients undergoing liver transplantation for viral hepatitis
Discuss recent studies regarding the risk factors for the development of hepatocellular carcinoma
Specify the latest data on the management of hepatitis in the injection drug user population
Assess factors that attribute to the progression of chronic liver disease

CREDIT INFORMATION

Release Date: January 14, 2008

Expiration Date: January 13, 2009

Physicians: maximum of 1.25 AMA PRA Category 1 Credits™

Registered Nurses: 1.2 Nursing contact hours

Pharmacists: 1.3 contact hours (0.13 CEUs)

Status: The activity is not currently available for credit.

Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.